UNSPSC 51391744: Colterol

This classification denotes a beta-adrenergic agonist with the molecular formula C12H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1WH11068UO chemically known as 1,2-benzenediol, 4-(2-)((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (+/-)- but generally known as colterol, which bears US NIH Compound Identifier 25104. European Medicines Agency schedules Colterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06802MIG.

UNSPSC 51391744 Colterol, a Commodity code, describes pharmaceutical products and formulations that state and local governments procure for emergency medical response, public health programs, and community health initiatives. The recent solicitation activity shows state and local bodies purchasing naloxone and drug deactivation systems for opioid overdose prevention and substance abuse mitigation, alongside exploratory procurement for direct-to-manufacturer pharmacy programs serving state employee health plans. Issuing bodies under this code include county health departments and state health and human services agencies, with Seminole County, Florida and the Texas Health and Human Services Commission representing recent activity. The scope of work encompasses the acquisition of finished pharmaceutical products and related medical supplies, delivered on quarterly or routine schedules to specified locations, with vendors required to manage logistics, comply with federal workplace and immigration verification standards, and carry standard commercial insurance.

Recent activity spans Florida and Texas. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor information on direct-to-manufacturer prescription fulfillment capabilities for a Therapeutic Pharmacy Initiative, a preliminary market-research phase designed to inform future formal competitive solicitation. Both procurements require vendors to submit documentation of drug-free workplace status and E-Verify compliance. The Seminole County contract carries a two-year initial term with one-year renewal option and includes a three-month probationary termination period.